Portfolio

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

February 26, 2024

Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble factors with the potential as pharmacodynamic and predictive response markers.

 

Read more